Abstract
Beneficial effects by both interferon-β and statin treatment in patients with multiple sclerosis (MS) may be linked to interference with the Th1/Th2 cytokine balance. We determined patterns of Th1/Th2 cytokines (interleukin (IL)-1β, IL-2, IL-6, IL-12p70, tumor-necrosis factor (TNF)-α and interferon-γ, and IL-4, IL-5 and IL-10, respectively) in the serum of patients with relapsing-remitting MS treated with 250 μg interferon-β 1b or with interferon-β plus 40 mg atorvastatin. In treatment naïve patients with MS, a trend for lower TNF-α serum levels compared to controls was detected ( P = 0.08). Interferon-β treatment increased TNF-α levels, while a trend for lowering of IL-5 serum levels was found ( P = 0.07). Addition of atorvastatin raised IL-12p70 serum levels ( P < 0.05). Mean levels of two Th2 cytokines (IL-4, IL-10) showed a non-significant increase after addition of atorvastatin. We conclude that interferon-β and atorvastatin exert divergent action on Th1/Th2 serum cytokines levels in MS. Supplemental atorvastatin might promote a Th1-type response by raising IL-12p70. Further studies are required to support a Th2 cytokine shift by atorvastatin in patients with MS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
